Finance entity
Against the same-window beat baseline of 28% negative, this entity's 0% share is less negative. At 5.3, the average consequence score sits below the same-window beat average of 6.3. Of the tracked stories, 2 of 6 also mention AbbVie, the most common co-covered peer.
Last mentioned: Aug 2, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Against the same-window beat baseline of 28% negative, this entity's 0% share is less negative. At 5.3, the average consequence score sits below the same-window beat average of 6.3. Of the tracked stories, 2 of 6 also mention AbbVie, the most common co-covered peer. Source depth averages 2 original sources per story, versus 2.8 across the same-window beat baseline. The 151-day window averages about 0.3 stories each week. The clearest coverage concentration is earnings: 3 of 6 stories, with the rest divided among 1 other category. We currently track 6 Finance stories that mention Johnson & Johnson, published between February 19, 2026 and July 19, 2026.
Computed from the 6 stories linked to this entity, with beat comparisons drawn from all 3629 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Johnson & Johnson. Shared-story counts are live from our verified record — not editorial picks.
BofA Target Increase
Bank of America raises price target based on pharmaceutical and MedTech pipeline strength.
Institutional Rebalancing
Richard Bernstein Advisors and Rathbones Group PLC report reduced holdings in JNJ.
Fast-Track Approval
FDA approves Tecvayli-Darzalex combination for blood cancer treatment.
FDA Approval & 12-Month High
JNJ receives FDA approval for multiple myeloma combo and stock hits a yearly peak.
Institutional Exit Revealed
13F filings reveal a $170 million divestment by a major institutional fund.
120% Gain Milestone
PTGX stock reaches a 120% gain milestone from its 52-week low.
J&J Partnership Milestone
Johnson & Johnson advances JNJ-2113 into late-stage trials, validating oral peptide tech.
Phase 3 Data Release
Positive Phase 3 data for rusfertide in polycythemia vera triggers initial stock rally.
The iShares U.S. Pharmaceuticals ETF (IHE) and iShares Global Healthcare ETF (IXJ) differ in expense ratios (0.39% vs 0.41%), AUM ($1.4B vs $4.1B), and diversification (56 vs 110 holdings). For finance professionals, the 0.02% fee gap may tip the scales for cost-conscious portfolios, but liquidity and global exposure often justify IXJ's slightly higher expense.
Source: Cory Renauer (us) · fool.com
As the market enters March 2026, investors are increasingly turning to 'Dividend Kings'—companies with over 50 consecutive years of dividend increases—as a defensive hedge against lingering volatility. This briefing analyzes the top three picks for the month: Procter & Gamble, Johnson & Johnson, and Coca-Cola, highlighting their resilience and compounding potential.
Source: finance.yahoo.com · fool.com
Bank of America has raised its price target for Johnson & Johnson, citing robust growth in the company's pharmaceutical and MedTech pipelines. The upgrade follows a series of FDA approvals and a strategic pivot toward high-margin innovative medicine after the Kenvue spinoff.
Legend Biotech and Core Molding Technologies released their full-year 2025 financial results, highlighting a period of strategic expansion and operational resilience. While Legend Biotech continues to scale its CAR-T therapy footprint, Core Molding demonstrated steady performance in the industrial manufacturing sector.
Protagonist Therapeutics shares have soared 120% following clinical and regulatory milestones, but a recent $170 million institutional exit is raising questions about the stock's near-term ceiling. The move highlights a growing divergence between retail momentum and institutional profit-taking in the biotech sector.
Genmab A/S reported full-year 2025 revenue of $3.72 billion, missing analyst estimates despite strong growth in its core oncology portfolio. The company is prioritizing long-term growth through its $1.8 billion ProfoundBio acquisition and the global rollout of Epkinly, leading to a temporary contraction in net profit margins.
Johnson & Johnson is linked from 6 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
